Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilize

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.